{"id":15579,"date":"2012-10-15T02:30:00","date_gmt":"2012-10-15T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/biotech-parte-della-soluzione-a-crisi\/"},"modified":"2012-10-15T02:30:00","modified_gmt":"2012-10-15T00:30:00","slug":"biotech-parte-della-soluzione-a-crisi","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/biotech-parte-della-soluzione-a-crisi\/","title":{"rendered":"Biotech part of the crisis solution"},"content":{"rendered":"

Meeker (Genzyme), Italy is part of the scientific community we need to create<\/span><\/i><\/b><\/p>\n

"It is certainly a very difficult moment from an economic point of view and health care represents an important burden" for public spending". But "as far as biopharmaceuticals are concerned, they represent a very small percentage of total healthcare costs. In Great Britain it is equal to less than 10% of expenditure, in the United States it is 12.5%,<\/p>\n

<\/font><\/font><\/span><\/p>\n

So I think that biopharmaceuticals, if used correctly and appropriately, are part of the solution rather than the problem, and can help lower costs, rather than drive them up". at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims) in Lyon.<\/p>\n

<\/font><\/font><\/span><\/p>\n

According to Meeker, instead of intervening in pharmaceuticals when costs need to be rationalised, "it would be necessary to look at those sectors which are not as efficient", he assures Pharmakronos.<\/p>\n

<\/font><\/font><\/span><\/p>\n

As for Italy's role in the global research scene, the manager states: "Innovation is not something that can be bought: you cannot give money to the smartest people in the world and think that they can give us a new drug What we have to do to keep innovating is to be part of a global community and Italy is a well-developed country from a scientific point of view, which absolutely must be part of this system".<\/p>\n

<\/font><\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 October 15, 2012 \u2013 PharmaKronos<\/p>\n

<\/span><\/i><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Meeker (Genzyme), Italia fa parte di comunita’ scientifica che dobbiamo creare “E’ sicuramente un momento molto difficile dal punto di vista economico e la sanita’ rappresenta un peso importante" per la spesa pubblica". Ma "per quanto riguarda la biofarmaceutica, essa rappresenta davvero una piccola percentuale dei costi sanitari totali. In Gran Bretagna e’ pari a …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15579"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15579\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}